Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2016-04-20
Target enrollment:
Participant gender:
Summary
Soluble Beta-Glucan (SBG) is a compound prepared from commercial active dry Baker's yeast
which is then proceeded through a multi-step laboratory processes invented by Prof. Rapepun
Wititsuwannakul, Faculty of Science, Prince of Songkla University, Thailand. Based upon
pre-clinical data, SBG has been shown to inhibit angiogenesis and probably enhance immune
function, leading to shrinkage of tumor size in athymic nude mice injected by hepatocellular
carcinoma cells (HepG2) and cervical cancer cells. Therefore, the investigators expect to see
the safety and anti-cancer property of SBG in patients with advanced cancer whom no available
therapy can be offered.